P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)

• F. B. Askeland,
• A.-M. Rasmussen,
• A. Lysen,
• E. Haukås,
• A. Eilertsen,
• M. Moksnes,
• G. Tsykunova,
• A. Vik,
• B. D. Eiken,
• J. H. Sørbø,
• J. Rolke,
• K. O. Sand,
• R. F. Hallstensen,
• L. Myrseth,
• T. S. Slørdahl,
• F. Schjesvold

Affiliations

F. B. Askeland

1 Oslo Myeloma Center, Department of Hematology

A.-M. Rasmussen

1 Oslo Myeloma Center, Department of Hematology

A. Lysen

1 Oslo Myeloma Center, Department of Hematology

E. Haukås

3 Department of Hematology and Oncology, Stavanger University Hospital, Stavanger

A. Eilertsen

4 Department of Hematology, Akershus University Hospital, Oslo

M. Moksnes

5 Cancer and Hematology Center, Vestfold Hospital, Tønsberg

G. Tsykunova

6 Department of Medicine, Haukeland University Hospital, Bergen

A. Vik

7 Department of Hematology, University Hospital of North Norway

B. D. Eiken

9 Department of Oncology, Hospital Østfold, Kalnes

J. H. Sørbø

10 Medical Department, Levanger Hospital, Levanger

J. Rolke

11 Department of Hematology, Sørlandet Hospital, Kristiansand

K. O. Sand

12 Department of Medicine, Ålesund Hospital

R. F. Hallstensen

15 Department of Hematology, Nordland Hospital, Bodø

L. Myrseth

1 Oslo Myeloma Center, Department of Hematology

T. S. Slørdahl

16 Department of Hematology, St. Olavs Hospital

F. Schjesvold

1 Oslo Myeloma Center, Department of Hematology